Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | BRPF1 | P55201 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.56 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | S100B | P04271 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL1842927 | 0.98 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2BRPF1KDM4EHSD17B10 | |
| Hydrochloric Acid SCHEMBL16736534 | 0.98 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2BRPF1KDM4EHSD17B10 | |
| SCHEMBL25406024 | 0.81 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2BRPF1KDM4EHSD17B10 | |
| SCHEMBL30349665 | 0.81 | HPD (0.49) | ALDH1A1SMN1; SMN2BRPF1KDM4EHSD17B10 | |
| SCHEMBL28968224 | 0.81 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2BRPF1KDM4EHSD17B10 | |
| SCHEMBL8351561 | 0.80 | PIK3CG (0.61) | ALDH1A1SMN1; SMN2BRPF1KDM4EHSD17B10 | |
| SCHEMBL10145973 | 0.80 | MAPK14 (0.48) | ALDH1A1SMN1; SMN2BRPF1KDM4EHSD17B10 | |
| SCHEMBL25408758 | 0.80 | BRPF1 (0.47) | ALDH1A1SMN1; SMN2BRPF1KDM4EHSD17B10 | |
| SCHEMBL25406066 | 0.79 | DRD2 (0.51) | ALDH1A1BRPF1KDM4EATAD2GAA | |
| SCHEMBL28968245 | 0.79 | PIK3CA (0.52) | ALDH1A1BRPF1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719391-A2 | TRIPLE KINASE INHIBITORS | Unogen Biotech Ltd. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-12590066-B2 | Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD (US) | 2026-03-26 | — | — | US | disclosed |
| WO-2025096771-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-113727972-B | Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof | 韩国科学技术研究院 | 2024-12-27 | — | — | CN | disclosed |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-12-19 | — | — | US | disclosed |
| WO-2024249831-A2 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-08 | — | — | US | disclosed |
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-03 | — | — | US | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
| EP-1120421-B1 | New triphendioxazine compounds | CLARIANT FINANCE BVI LTD (VG) | 2005-02-09 | — | — | EP | disclosed |
| US-6617453-B1 | Preparing these triphendioxazine compounds by a cyclization step conducted in the presence of manganese dioxide and concentrated sulphuric acid. | CLARIANT FINANCE (BVI) LIMITED (VG) | 2003-09-09 | — | — | US | disclosed |
| EP-0911337-B1 | Process for the preparation of triphendioxazine compounds | CLARIANT FINANCE BVI LTD (VG) | 2003-02-26 | — | — | EP | disclosed |
| US-6355795-B1 | PIGMENTS POSSESSING HIGH FASTNESS TO SOLVENTS, MIGRATION AND LIGHT, WHICH HAVE GOOD THERMAL STABILITIES AND HIGH TINTING POWER AND ARE ALSO EASILY DISPERSIBLE | CLARIANT FINANCE (BVI) LIMITED (BV) | 2002-03-12 | — | — | US | disclosed |
| EP-1120421-A2 | New triphendioxazine compounds | Clariant Finance (BVI) Limited (VG) | 2001-08-01 | — | — | EP | disclosed |
| EP-1120420-A2 | New triphendioxazine compounds | Clariant Finance (BVI) Limited (VG) | 2001-08-01 | — | — | EP | disclosed |
| US-6255482-B1 | PREPARING CHLORINE-CONTAINING TRIPHENDIOXAZINE COMPOUNDS USEFUL AS PIGMENTS POSSESSING HIGH FASTNESS TO SOLVENTS, MIGRATION, AND LIGHT, WHICH HAVE GOOD THERMAL STABILITIES AND HIGH TINTING POWER | CLARIANT FINANCE (BVI) LIMITED (VG) | 2001-07-03 | — | — | US | disclosed |
| EP-0911337-A1 | New triphendioxazine compounds | Clariant Finance (BVI) Limited (VG) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | ALK, ERBB2, ERBB3 | ALDH1A1 2170/4885SMN1; SMN2 3559/4885BRPF1 4188/4885 |
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | ALDH1A1 1306/4885SMN1; SMN2 1657/4885BRPF1 2227/4885 |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | ALDH1A1 1654/4885SMN1; SMN2 3864/4885BRPF1 116/4885 |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | RAF1, CHEK1, BRAF | ALDH1A1 2759/4885SMN1; SMN2 3254/4885BRPF1 2129/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | ALDH1A1 1008/4885SMN1; SMN2 4531/4885BRPF1 1796/4885 |
| US-12590066-B2 | Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CLIC1 | ALDH1A1 592/4885SMN1; SMN2 2395/4885BRPF1 4446/4885 |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | ALDH1A1 1654/4885SMN1; SMN2 3864/4885BRPF1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.